AstraZeneca CEO: 2020 Approval For COVID Vaccine Still Possible
Soriot Says Speed Has Not Compromised Safety
While AZ awaits an independent review, its CEO maintains the vaccine could soon be back on track for a late 2020/early 2021 approval.
You may also be interested in...
Confidence in the vaccine has slipped in the US, regardless of political affiliation.
Neither has announced a firm timeline, and the difference between Pfizer's 'October' and Moderna's 'November' could be mere hours or a few weeks, but Pfizer, by dint of luck or experience, is now in a position to offer the more optimistic projection on when it will seek an EUA. Both firms release their Phase III trial protocols, which seem in line with US FDA guidance.
A choice asset in the middle of a pandemic, pharma companies could see the investment bubble burst once normalcy is on the horizon. But interest will continue in innovators, rather than big pharma specifically, predicts an expert panel featuring Biogen's chairman, a former Sanofi CEO and an ex-NIH director.